PMV Pharmaceuticals, Inc.
PMVP · XNASCIK 1699382fmd_13SCB15MJD9V5TRK89Q2GRHK1CManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2018 to Sep 30, 2026, 32 periods
| Line item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Net interest income | 1 | 1 | 1 | 0 | 4 | 11 | 11 | 6 |
| Research and development | 14 | 21 | 24 | 36 | 52 | 56 | 59 | 70 |
| Total operating expenses | 19 | 27 | 35 | 58 | 77 | 80 | 85 | 86 |
| Operating income | (19) | (27) | (35) | (58) | (77) | (80) | (85) | (86) |
| Other non-operating income (expense) | 1 | 1 | 1 | 0 | 4 | 11 | 11 | 6 |
| Income before taxes | (18) | (25) | (34) | (58) | (73) | (69) | (75) | (80) |
| Income tax expense | 0 | 0 | 0 | 0 | (0) | 0 | (16) | (2) |
| Net income from continuing operations | (18) | (25) | (34) | (58) | (73) | (69) | (59) | (78) |
| Net income | (18) | (25) | (34) | (58) | (73) | (69) | (59) | (78) |